Sidra’s Chief Research Officer and SITC President Dr Francesco Marincola speaking at the conference.
DOHA: A discussion on new treatment methods for cancer focus on latest research advances, with a special attention on currently approved and emerging tumor immunotherapy approaches.
Sidra Medical and Research Center and the Society for the Immunotherapy of Cancer (SITC) hosts the ‘Updates on Immunotherapy of Cancer and Immunoscore’ event, with the leading authorities in oncology and immunotherapy travelling to Doha to share the latest research on novel cancer treatments, which use the body’s own protective response.
Immunotherapy uses the immune system’s T-cells to find and kill cancerous cells while avoiding the damage to healthy tissue commonly caused by many of the current forms of treatment, such as radiation therapy, chemotherapy and surgery.
Sidra’s Chief Research Officer and SITC President Dr Francesco Marincola said: “Our immune system is elegantly structured to recognise self from non-self, vigorously attacking cells deemed foreign. The goal of cancer immunotherapy is to understand these mechanisms and to promote anti-tumor immune responses. I am honoured that the world’s top minds in immunotherapy research and practice are taking part in this meeting, which will spur international collaborations and further this breakthrough research. Genetics and disease risk assessment will be one of the Centers of Excellence at Sidra and we look forward to continuing our relationship with SITC and other international institutions in the immunotherapy arena to bring personalised treatments to patients.”
Over the course of the two-day programme, world-wide leaders and visionaries in the field of cancer immunotherapy are discussing ways to improve the outcome for patients with cancer by incorporating strategies based on cancer immunotherapy.